Using the recombinant human HER2 extracellular domain (ECD) protein as a reference, this study confirms a dose–response-dependent release of HER2 ECD protein (referred to simply as HER2 or rHER2 for the remainder of this manuscript), which could induce anti-tumor immune responses. This evidence concerns the gene ERBB2 and neoplasm.